Expanding Horizons: The Present and Future of Bispecific Antibodies Across Oncology

Panelists discuss how recent FDA approvals for bispecific antibodies in oncology, particularly for hematologic malignancies like multiple myeloma and lymphomas, represent significant treatment advances, while highlighting expanding applications in solid tumors, autoimmune disorders, and infectious diseases as promising growth areas for this therapeutic modality.

Experts discuss how the availability of bispecific therapies has influenced treatment paradigms in oncology and how bispecifics fit into current treatment algorithms for hematologic malignancies and solid tumors.

Experts discuss which patient populations stand to benefit the most from recently approved bispecific therapies, identifying gaps or opportunities for further patient benefit, as well as the data gaps that exist in understanding the optimal use of bispecific antibodies across various cancer types.

Experts discuss the benefits of implementing and operationalizing bispecifics in the community oncology setting.

Experts discuss the most common logistical challenges encountered when implementing bispecific therapies as well as the primary barriers smaller community practices face in operationalizing bispecific antibody treatments.

Experts discuss what partnerships between academic and community settings look like with regard to bispecifics, highlighting the role academic centers play in supporting community practices with bispecific therapy protocols.

Experts discuss how institutions can develop standardized operational workflows that accommodate multiple bispecific products with different administration requirements, particularly as more products become available.